Brand Information

Strength	Rate	Packing Style
5mg	147.00	10s tablets
10mg	213.00	10s tablets

Drug Interaction:

Agents for Migraine include- Almotriptan, Eletriptan, Frovatriptan, Naratriptan, Rizatriptan, Sumatriptan, Zolmitriptan Refer - Sumatriptan

Indication:

Agents for Migraine include- Almotriptan, Eletriptan, Frovatriptan, Naratriptan, Rizatriptan, Sumatriptan, Zolmitriptan

Refer - Sumatriptan

Patent Expiry Date of drugs (Ref - IDMA Publication)

Chemical Category Manufacturer/ US Patent

Ingredient- Marketer Expiration Date

Rizatriptan CNS Merck & Co. 28-01-2013

New Drugs Approved by (DCI) Drug Controller GENERAL - India For Marketing

(Ref- IDMA Publication)

Name of Drug Indication Date of Approval

1.Rizapritan Anti-migraine 27-02-2003

2.Rizapritan Benzoate Orally 24-05-2010

Distegrating agent 10mg

Addl.Dosage Form

Same as already approved

Adverse Reaction:

Serious coronary vasospasm , transient mycardial ischemia, ventricullar fibrillation/ tachycardia, amd MI have been associated with 5-HT1 agonists.

Oral - these agents have been well tolerated. Across all doses most adverse reactions have been mild and transcient aand did not lead to long lasting effects.

Cardiovascular- palpitation , arrhythmia, bradycardia, cold extremities, hypertension, tachycardia, angina pectoris.

CNS- euphoria, hypesthesia, mental acuity decreased , tremor, agitation, anxiety, confusion, depression,disorientation, dream abnormality, dysarthria, gait abnormality, hyperesthesia, insomnia, irritability, memory impairment, nervousness, vertigo, akineesia/bradycardia, apphrension, depersonalisation,dysesthesia, hyperkinesia, hyporeflexia

Dermatologic- flushing, priritus, rash, sweating, urticaria, acne, erythema, photosensitivity.

GI- diarrhea, vomiting, acid regurgitation, constipation, dyspepsia, dysphagia, flatulance, thirst, edema, anorexia, appetite increased, eructation, gastritis, paralysis ( tongue ) GU - hot flashes, menstruation disorder, polyuria, urinary frequency, dysuria.

Musculoskeltal - arthalgia, muscle cramp, muscle spasm, muscle weakness, musculoskelatal pain, myalgia, stiffness

Respiratory- dyspnea, congestion, dry nose, dry throat, epistaxis, nasal irritation,phrayngitis, respiratory congestion ( nasal) , sinus disorder, upper respiratory tract infection, yawning, cough, hiccoughs, hoarseness, phyrayngeal edema, rhinnorhea, sneeszing, tachcardia

Special senses- blurred vision, burning eye, dry eyes, ear pain, eye irritation,teraing, tinnitus, eye swelling, hyperacusis, itching eye, photophobia, photopsia, smell pervertion.

Miscellaneous- warm/cold sensation, abdominal distention, chills, dehydration, facial edema, hangover effect, heat sensitivity, edema//swelling, fever, orthostic efects, syncope.

Contra-Indications:

Injectable preparation used IV because of potential to cause coronary vasospasm,

patients wit ischemic heart disease ( angina pectoris )

history of MI , strokes, ischemic attacks TIAs or

documented silent ischemia

Prinzmetal variant angina or significant underlying cardiovascular disease

Concurrent use of ( use within 24 hours of ) ergot containg prepn or ergot type medications

such as dihydroergotamine or methysergide

Concurrent monoamine oxidase inhibitors MAOI therapy ( or within 2 weeks of discontinuing an MAOI ( except eletriptan )

Naratriptan and sumitriptan - cerbrovascular or peripheral vascular syndromes, severe impairment,( child Pugh grade C) severe renal impairment (Ccr less than 15mL/min ( naratriotan only)

Frovatriotan and eletriptan - peripheral vascular disease

Eletriptan - severe hepatic impairment

Warnings/precautions-

Risk of myocardial ischemia or MI and other adverse cardiac events-

because of the potential of these compounds to cause coronary vasospasm, do not give these agents to patients with documented ischemic or vasopastic coronary artery disease

It is strongly recommended that that 5-HT1 agonists not be given to patients in whom unrecognized coronary artery disease CAD is predicted by the presence of risk factors eg. hypertension,hyperchloesrolemia, smoking, obesity, diabetes, strong family history of CAD, female with surgical or physilogical menopause or male older than 40 years of age)

unless a cardiovascular evaluation provides satisfactory clinical evidence that the patient is reasonably free of coronary artery and ischemic myocardial disease or significant underlying cardiovascular disease

Zolmitriptan- there is a report of at least 1 patient experiencing coronary vasospasm without the history of cardiac disease and with documented history of absence of CAD.

Patients with symptomatic Wolff- Parkinson -White syndrome or arrhthmias associated with cardiac accessory conduction pathway disorders should not receive zolmitriptan

Cardiac events and fatalities associated with 5-HT1 agonists-

serious adverse cardiac events including acute MI , life threatening disturbances of cardiac

rhythm, and death have been reported within few hours following admin. of 5- HT1 agonists.

Considering the use of 5 - HT1 agonists in patients with migraine , the incidence of these events is extremely low.

Cerbrovascular events and fatalities with 5-HT1 agonists-

cerebral hemorrhage , subarachnoid hemorrhage , stroke, and other cerebrovascular events have been reported in patients treated with 5-Ht1 agonists and some have resulted in fatalites.

It should be noted that patients with migraine may be at increased risk of certain cerebrovacular events eg. stroke, hemorrhage, TIA

Other vasospasm related events- 5-HT1c agonists may cause vasospatic reactions other than coronary artery vasospasm . Peripheral vascular ischemiand colonic ischemia with abdominal pain and bloody diarrhea have been reported with 5-HT1 agonists.

Increase in blood pressure- significant increase in blood pressure including hypertensive crisis have been reported on rare occassions in patients with a history of with or without hypertension trreated with 5HT1 agonists.

5-HT1 agonists are contraindicated in patients with uncontrolled hypertension.

Renal function impairment-

Use rizatriptan and sumitriptan with caution in dialysis patients becausec of decrease in clearance

Hepatic function impairment-

Administer with caution to patients with diseases that may alter the absorption,metabolism,

or excretion of drugs.

Photosensitivity-

Photosenrization may occur. Caution patients to take protective measures

Use during pregnancy only if the potential benefits justifies the potential risk to the fetus

Lactation-

Sumatriptan and eletriptan are excreted in human breast milk.

Lactating rats dosed with zolmitriptan had milk levels equivalent to maternal plasma levels at 1 hour and 4 times higher than plasma levels at 4 hours

Naratriptan -related material is excreted in milk of rats.

Rizatriptan is extensively excreted in rat milk at a level 5-fold or greater than matenal plasms levels

Frovatriptan and its metabolites are excreted in the milk of lactating rats with maximum concentration being 4 fold than seen in blood.

Excercise caution when administering to a nursing woman

Children- safety and efficacy have not beenestablished.

Elderly- Pharmacokinetics disposition of 5-HT1 agonists in the elderly is similar to that seen in younger adults.

Dosages/ Overdosage Etc:

Migraine

Dosage-

Initially 5-10mg swallowed whole with liquid. Repeat if necessary after at least 2 hours. Maximum 30mg per day. Not receommended for patients below 18 years

Patient Information:

Injection- sumitriptan- Instruct patients who are advised to self administer sumatriptan in medically unsupervised situations, on the proper use of the product prior to doing so for the first time, including loading the auto-injector and discarding empty syringes For adults the usual dose is a single injection given just below the skin.

Administer as soon as migraine symptoms appear, but it may given at any time during the attack. A second injection can be given if symptoms of migraine return. Do not use more than 2 injections/24 hours and allow at least 1 hour between each dose.

The patient may experience pain or redness at the site of injection, but this usually lasts less than 1 hour. Intranasal- for adults, Usual dose is a single nasal spray into 1 nostril. If headache returns, a second nasal spray may be given 2 hours after the first spray.

For any attack where the patient has no response to the first nasal spray, do not use a second nasal spray without consulting a physician Do not administer more than 40mg sumatriptan or more than 10mg zolmitriptan nasal spray in any 24 hour period.

Oral- Take a single dose with fluids as soon as symptoms of migraine appear. A second dose may be taken if symptoms return, but no sooner than 2 hours ( sumatriptan, zolmitriptan, eletriptan ) or 4 hours ( naratriptan, ) following the first dose. For a given attack if there is no response to the first dose do not take a second dose without first consulting a physician.

Do not take more than 200mg sumatriptan, more than 5mg naratriptan, more than 10mg zolmitriptan or more than 80mg eletriptan in any 24 hours period. Tell a physician if the patient has risk factors for heart disease (eg. high blood pressure, high cholesterol, obesity, diabetes, smoking, strong family history of heart disease or stroke, a male over 40 years of age postmenopausal women ) These agents are intended to relieve migraine but not to prevent or reduce the number of attacks.

Use only to treat an actual migraine attack or cluster headache ( sumatriptan inj only ) Instruct patients not to use these agents if they are pregnant, think that they might be pregnant, are trying to become pregnant, or not taking adequate contraception , unless they have discussed this with their physician If pain, tightness, pressure or heaviness in the chest , throat, neck or jaw occurs when using these agents, instruct patients to discuss it with a physician before using more.

If the chest pain is severe or does not go away, instruct patients to immediately call a physician If sudden or severe abdominal pain occurs following naratriptan or sumatriptan admin., instruct patient to immediately call a physician If shortness of breath, wheezing ,heart throbbing, swelling of eye lids, face or lips, skin rash, skin lumps, or hives occur, advice patients to immediately tell a physician . Instruct patients not to take additional dose unless directed by the physician. If feelings of tingling, heat, flushing ( redness of face lasting for a short time) heaviness, pressure, drowsiness, dizziness, tiredness, or sickness develop, instruct patients to tell a physician Migraine or treatment with Rizatriptan may cause somnolence in some patients. Dizziness also has been reported. Evalute ability to perform complex tasks during migraine and after administration of Rizatriptan.

Instruct patiens not to remove the blister from the outer pouch until just prior to dosing zolmitriptan or rizatriptan orally -disintegrating tablets. Instruct patients to peel blister packs open with dry hands and to place orally-disintegrating tablets on the tongue,where it will dissolve and be swalllowed with the saliva. Inform phenylketonuric patients that riztriptan and zolmitriptan orally-disintegrating tablets contain phenylalamine ( a component of aspartame )

Each 5mg rizatriptan orally -disintegrating tablet contains 1.05mg phenylalamine and each 10mg orally-disintegrating tablet contains 2.1mg phenylalamine. Each 2.5 mg zolmitriptan orally-disintegrating tablet contains 2.81 mg phenylalamine Photosensitization ( photoallergy or photoxicity ) may occur. Therefore, caution patients to take protective measures (ie. sunscreens, protective clothing ) against exposure to sunlight or ultraviolet light until tolerance is determined

Pharmacology/ Pharmacokinetics:

Agents for Migraine include- Almotriptan, Eletriptan, Frovatriptan, Naratriptan, Rizatriptan, Sumatriptan, Zolmitriptan

Pharmacology- Sumatriptan, naratriptan, zolmitriptan, rizatriptan, frovatriptan, eletriptan and almotriptan are selective 5-hydroxytryptamine1 (5-HT1 or serotonin ) receptor agonists

Pharmacokinetics- RENAL FUNCTION IMPAIRMENT -- Rizatriptan- in hemodialysis patients ( Ccr less than 2mL/min/ 1.73m2 ) the AUC for rizatripotan wasc approximately 44% greater than that in patients with normal renal function.

HEPATIC FUNCTION IMPAIRMENT- liver plays an important role in presystemic clearance of 5-HT1 agonists. Accodingly the bioavailability may be markedly increased in patientsdwith liver disease. Rizatriptan- following oral admin in patients with hepatic impairment caused by mild to mloderate alcoholic cirrhosis of the liver , plasma concn. of rizatriptan were similar in patients with mild to hepatic insufficiency compared with a control group of healthy subjects, plasma concentration of rizatriptan were approx. 30% greater in patients with moderate hepatic insufficiency.

Interaction with Food:

Food has significant effect on oral 5-HT1 agonists bioavailability, but delays sumatriptans Tmax by aaproximately 30 minutes and rizatriptans time to reach peak concentration by 1 hour. AUC and Cmax of eletriptan are increased approximately 20% to 30% following oral admin. of a high fat meal.

Pregnancy and lactation:

Pregnancy- There are no adequate and well controlled studies in pregnant women

Use during pregnancy only if the potential benefits justifies the potential risk to the fetus

Lactation- Excercise caution when administering to a nursing woman

Children- safety and efficacy have not beenestablished.

Elderly- Pharmacokinetics disposition of 5-HT agonists in the elderly is similar to that seen in younger adults.

RIZACT

Drug Interaction

Indication

Adverse Reaction

Contra-Indications

Dosages/ Overdosage Etc

Patient Information

Pharmacology/ Pharmacokinetics

Interaction with Food

Pregnancy and lactation